Get the Daily Brief
Latest Biotech News
Takeda taps Iambic’s AI — $1.7bn discovery pact
Takeda signed a multiyear discovery and technology collaboration with Iambic Therapeutics reportedly worth $1.7 billion, aiming to accelerate small‑molecule drug discovery across oncology, GI and...
Startups raise fresh capital: ILiAD $115M; Galux $29M
ILiAD Biotechnologies closed an oversubscribed $115 million Series B to advance its whooping cough vaccine toward pivotal Phase 3 studies. The financing is sized to support late‑stage data accrual...
AI drug engines accelerate: Isomorphic claims advance; Insilico expands
Isomorphic Labs announced what it called a major advance in its AI drug‑design engine after rolling out AlphaFold‑derived models in prior years; the company claims enhanced capability to convert...
Ovrlpy exposes 3D overlaps in spatial transcriptomics
Researchers published ovrlpy, a software tool that identifies vertical (z‑axis) signal overlaps and tissue folds in spatial transcriptomics data, exposing a class of artifacts that can confound...
Smart vascular grafts: magnetoelastic sensors enable real‑time stenosis monitoring
Multiple Nature Biotechnology reports described a hemodynamics‑driven magnetoelastic vascular graft that restores flow while wirelessly and continuously diagnosing stenosis in animal models. The...
Medicare covers Personalis’ NeXT Personal MRD test for lung cancer surveillance
The US Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal molecular residual disease (MRD) test for surveillance in stages I–III non‑small cell lung cancer....
Lilly buys Orna: $2.4B bet on in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics in a transaction valued at up to $2.4 billion to gain an in‑vivo CAR‑T capability built on circular RNA and LNP delivery. Lilly framed the deal as a...
FDA rejects Regenxbio therapy: Hunter syndrome bid turned down
The FDA issued a complete response letter rejecting Regenxbio’s RGX‑121 gene therapy for Hunter syndrome, citing concerns about the development program’s ability to define the patient population...
Novo Nordisk sues Hims – Wegovy compounding clash escalates
Novo Nordisk filed patent litigation against Hims & Hers over a compounded pill version of semaglutide marketed by Hims, accusing the telehealth company of unlawfully mass‑marketing an unapproved...
Medicare covers Personalis MRD test: lung cancer surveillance win
The US Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal molecular residual disease (MRD) test for surveillance in stages I–III non‑small cell lung cancer....
Circular Genomics licenses circRNA Alzheimer’s IP from WUSTL, MDC
Circular Genomics secured exclusive commercial rights to intellectual property from Washington University in St. Louis and the Max Delbrück Center covering circular RNA (circRNA) biomarkers for...
Eczema drug race... Evommune and Nektar post encouraging long‑term data
Two late‑stage atopic dermatitis programs reported data that investors and clinicians judged noteworthy. Evommune reported positive phase 2a results for EVO301, an IL‑18 fusion protein, achieving...
Takeda inks $1.7B AI pact – Iambic collaboration formalized
Takeda announced a multiyear, large‑value partnership to integrate Iambic’s AI discovery platform into its small‑molecule R&D efforts across oncology, gastrointestinal and inflammation targets....
Thermo Fisher prices $3.8B notes: financing Clario acquisition
Thermo Fisher Scientific priced $3.8 billion of senior notes across maturities to help fund its pending $8.8 billion acquisition of clinical trial data platform provider Clario Holdings. The debt...
Waters completes BD biosciences buy – integration starts
Waters completed its $18.8 billion acquisition of Becton Dickinson’s Biosciences & Diagnostics business and outlined an initial integration plan to capture instrument replacement cycles,...
Capsida confirms cerebral edema in trial fatality; probe continues
Capsida Biotherapeutics reported that an autopsy identified cerebral edema as the immediate cause of death in a patient dosed in its suspended SYNRGY trial testing an AAV gene therapy for STXBP1...
Lilly snaps up Orna: $2.4bn bet on in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics in a deal worth up to $2.4 billion to secure an in‑vivo CAR‑T and circular RNA platform. Orna’s lead program, ORN‑252, is described as clinical‑trial...
FDA rejects Regenxbio: Hunter syndrome therapy turned down
The FDA issued a complete response letter rejecting Regenxbio’s RGX‑121 for Hunter syndrome, the company said. The regulator flagged concerns over the trial design, including the reliance on a...
Capsida confirms cerebral edema — probe continues
Capsida Biotherapeutics reported that an autopsy confirmed cerebral edema as the cause of death in a patient treated in its suspended SYNRGY trial of CAP‑002 (AAV gene therapy for STXBP1). The...
Generate files IPO: GB‑0895 advances into Phase III
Generate Biomedicines filed for an IPO days after dosing the first patient in Phase III with GB‑0895, an AI‑designed anti‑TSLP antibody for severe asthma. The company said proceeds will fund...